| abstract |
The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). More specifically, this invention relates to a method of treating cancer by administering an anti-TIM-3 antibody in combination with an anti-PD-Ll/ ΤΟΡβ Trap fusion protein. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model. |